Biose Industrie

Biose Industrie is a leading Contract Development and Manufacturing Organization (CDMO) specializing in microbiome therapeutics and Next-Generation Probiotics (NGPs).

Founded in 1951 in Aurillac, France, the company operates a 52,000m2 center of excellence and a technology transfer lab in Boston, USA. With a workforce of 201–500 employees, Biose Industrie was recently acquired in a €80m buyout by L-GAM Advisers and the French State. The company offers comprehensive services, including process development and GMP drug product manufacturing for Live Biotherapeutic Products (LBPs). Biose Industrie has expertise in strict anaerobes, complex co-cultures, and high-potency formulations, supporting both clinical and commercial supply. Its product range includes capsules, sachets, vials, liquids, and bulk powders, along with bacteria-based Active Pharmaceutical Ingredients (APIs) and microbiome-based ingredients. Biose Industrie is drug-GMP certified and complies with ANSM, EMA, and FDA regulations, making it a trusted partner for biotechnology, pharmaceutical, and consumer-focused companies.